Pd43-06 Methodology to Establish Non-Invasive Synchronous Heart Rate and Heart Rate Variability Measurement During Uroflowmetry to Examine Associations Between Cardiovascular Disease and Lower Urinary Tract Symptoms

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Overactive Bladder I (PD43)1 May 2024PD43-06 METHODOLOGY TO ESTABLISH NON-INVASIVE SYNCHRONOUS HEART RATE AND HEART RATE VARIABILITY MEASUREMENT DURING UROFLOWMETRY TO EXAMINE ASSOCIATIONS BETWEEN CARDIOVASCULAR DISEASE AND LOWER URINARY TRACT SYMPTOMS Kyle Brian Zuniga, Anne L. Ackerman, Michele Torosis, Victor Nitti, Andrew Macnab, and Lynn Stothers Kyle Brian ZunigaKyle Brian Zuniga , Anne L. AckermanAnne L. Ackerman , Michele TorosisMichele Torosis , Victor NittiVictor Nitti , Andrew MacnabAndrew Macnab , and Lynn StothersLynn Stothers View All Author Informationhttps://doi.org/10.1097/01.JU.0001009568.19060.25.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Heart rate (HR) and heart rate variability (HRV) are established measures related to cardiovascular disease (CVD), a known risk factor correlated with lower urinary tract symptoms (LUTS) and overactive bladder (OAB). However, there is no standardized methodology to relate changes in HR and HRV to gold standard methods of uroflowmetry. Objective: To describe a methodology and test feasibility of synchronous, noninvasive measurement of HR and HRV, detrusor activity, and uroflowmetry. METHODS: Equipment: the portable, wireless, continuous wave near-infrared spectroscopy (NIRS) instruments, Poralite and Portamon (Artinis Medical Systems), use NIR light at 785, 808, and 830 nanometers. Three optodes on each device are set at 30, 35, and 40 mm from the receiver and collect raw optical data at a sampling time of 25-100Hz. Protocol: Study subjects with and without LUTS provided data on demographics, medical history, and voiding symptoms through the validated International Consultation on Incontinence Questionnaire (ICIQ). Subjects then wore the Portalite over the frontal cortex (HR and HRV monitoring) and the Portamon suprapubically (detrusor oxygenation monitoring). Device recording was linked synchronously to a uroflow scale. Subjects were recorded for a 1-minute pre-void baseline, during voiding, and a 1-minute post-void baseline. RESULTS: N=26 (12 controls, 14 cases) completed the protocol. Among controls versus cases, average age was 34+6 and 58+18 (p<0.01), 9 (75%) and 13 (93%) subjects were women (p=0.21), and body mass index was 27+6 and 30+5 (p=0.19). Average ICIQ score was 1.7+1.7 and 15+5.7 (p<0.01) among women and 2.3+2.1 and 12 among men. The NIRS instruments accurately monitored HR, HRV, detrusor oxygenation, and uroflowmetry in all cases. A representative measurement is seen in Figure 1. CONCLUSIONS: Synchronous, wireless monitoring of HR, HRV, detrusor activity, and uroflowmetry using non-invasive NIRS devices is feasible and generates reproducible, accurate results. This method will allow for larger scale studies using NIRS for performing noninvasive uroflowmetry and analyzing the impact of normal versus pathologic cardiovascular function on LUTS and OAB. Download PPT Source of Funding: UCLA H & H Lee Surgical Research Scholars Program © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e900 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Kyle Brian Zuniga More articles by this author Anne L. Ackerman More articles by this author Michele Torosis More articles by this author Victor Nitti More articles by this author Andrew Macnab More articles by this author Lynn Stothers More articles by this author Expand All Advertisement PDF downloadLoading ...